Below is a list of trial sites by state that are actively recruiting participants. These site listings are sponsored by Corporate Members of the Sjögren's Foundation.
Chandler
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-301)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Amer Al-Khoudari, MD
Arizona Research Clinic PLLC
604 W Warner Rd Ste C3, Chandler,
Arizona 85225-2915
Contact: Divya Chauhan
Phone: (480) 556-1359
Email Address: divya.chauhan@azarthritis.com
Flagstaff
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-301) and (HZNP-DAZ-303)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Alexander Hu, DO
Arizona Arthritis and Rheumatology Associates - Flagstaff
399 S Malpais Ln Ste 108, Flagstaff,
Arizona 86001-6299
Contact: Thomas Huck
Phone: (480) 350-7655
Email Address: thomas.huck@azarthritis.com
Gilbert
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-301) and (HZNP-DAZ-303)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Daniel Kreutz, MD
Arizona Arthritis and Rheumatology Associates - Gilbert
3645 S Rome St Ste 201, Gilbert,
Arizona 85297-7338
Contact: Lynea Klemmedson
Phone: (480) 443-8400
Email Address: lynea.klemmedson@azarthritis.com
Glendale
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-301) and (HZNP-DAZ-303)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Saima Chohan, MD
Arizona Arthritis and Rheumatology Associates - Glendale
5681 W Beverly Ln Ste 100, Glendale,
Arizona 85306-9800
Contact: Revathi Pillai
Phone: (480) 626-6650
Email Address: revathi.pillai@azarthritis.com
Mesa
Phase 2 Study
HZN-1116 (HZNP-HZN-1116-201)
Horizon Therapeutics, now part of Amgen
Sjögren’s Disease (moderate to severe symptomatic and/or systemic disease) Clinical Trial
Areena Swarup, MD
Arizona Arthritis and Rheumatology Research- Mesa
2152 S. Vineyard Ave. Suite 129, Mesa,
Arizona 85210
Contact: Francesca Ingram
Phone: (480) 321-8581
Email Address: francesca.ingram@azarthritis.com
Phoenix
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-303)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Amer Al-Khoudari, MD, FACR
Arizona Research Clinic PLLC
4550 E Bell Road, Building 8, Ste 272, Phoenix,
Arizona 85032
Contact: Francesca Ingram
Phone: (602) 368-9667
Email Address: francesca.ingram@azarthritis.com
Phoenix
Phase 2 Study
HZN-1116 (HZNP-HZN-1116-201)
Horizon Therapeutics, now part of Amgen
Sjögren’s Disease (moderate to severe symptomatic and/or systemic disease) Clinical Trial
Matthew Herrmann, MD
Arizona Arthritis and Rheumatology Associates - Paradise Valley
4550 E. Bell Rd. Suite 170, Phoenix,
Arizona 85032
Contact: Ramya Rameshkumar
Phone: (480) 626-6657
Email Address: ramya.rameshkumar@azarthritis.com
Tucson
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-301)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Jeffrey Loomer MD
Arizona Arthritis and Rheumatology Associates - Tucson
2001 W Orange Grove Rd Ste 104, Tucson,
Arizona 85704-1140
Contact: Rishika Bysani
Phone: (520) 332-2952
Email Address: rishika.bysani@azarthritis.com
Tucson
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-303)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Jeffrey Loomer MD
Arizona Arthritis and Rheumatology Associates - Tucson
2001 W Orange Grove Rd Ste 104, Tucson,
Arizona 85704-1140
Contact: Laronda Lee
Phone: (480) 443-8400
Email Address: laronda.lee@azarthritis.com
Beverly Hills
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-301) and (HZNP-DAZ-303)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Daniel Wallace, MD
Wallace Rheumatic Studies Center, LLC
8750 Wilshire Blvd Ste 210, Beverly Hills,
California 90211-2703
Contact: Erin Avila
Phone: (310) 652-0920
Email Address: erin@walleemed.com
Covina
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-303)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Samy Metyas, MD
Samy Metyas MD, Inc.
500 W. San Bernardino Ave. Ste. A, Covina,
California 91723
Contact: Victoria Torres
Phone: (562) 758-6600
Email Address: victoria@medvinresearch.com
La Jolla
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-301)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Monica Guma Uriel, MD
UCSD Altman Clinical and Translational Research Institute Building
9452 Medical Center Drive, La Jolla,
California 92093
Contact: Bosco Trinh
Phone: (858) 246-2387
Email Address: botrinh@health.ucsd.edu
Napa
Phase 2 Study
HZN-1116 (HZNP-HZN-1116-201)
Horizon Therapeutics, now part of Amgen
Sjögren’s Disease (moderate to severe symptomatic and/or systemic disease) Clinical Trial
Eric Grigsby, MBA, MD
Neurovations
3444 Valle Verde Dr, Napa,
California 94558-2415
Contact: Hilary Cromwell
Phone: (707) 252-9660
Email Address: hilary@neurovations.com
Riverside
Otsuka Phase 2 Study
Sibeprenlimab
Otsuka Pharmaceutical
Chandrakant Mehta
Medvin Clinical Research – Riverside
21833 Cactus Ave, Riverside,
California 92518-3011
Contact: Alice Davis
Phone: +1 951-924-6500
Email Address: alice@medvinresearch.com
San Francisco
Deucravacitinib (IM011-1069) Phase 3
Deucravacitinib (IM011-1069)
Bristol Myers Squibb
Sjögren’s Clinical Trial (Systemic)
John Gonzales, MD
UCSF- University of California San Francisco
513 Parnassus Avenue, San Francisco,
California 94143
Contact: Francisco Quintanilla Mejia
Email Address: francisco.quintanilla@ucsf.edu
Santa Monica
Deucravacitinib (IM011-1069) Phase 3
Deucravacitinib (IM011-1069)
Bristol Myers Squibb
Sjögren’s Clinical Trial (Systemic)
Orrin Troum, MD
Providence St. John's Health Center
2336 Santa Monica Blvd Ste 207, Santa Monica,
California 90404
Contact: Donna Cruz
Phone: (310) 449-1999
Email Address: donna.cruz@providence.org
Tujunga
Otsuka Phase 2 Study
Sibeprenlimab
Otsuka Pharmaceutical
Dan La
Medvin Clinical Research – Tujunga
6673 Foothill Blvd, Tujunga,
California 91042-2706
Contact: Diana Martinez
Phone: +1 213-281-5146
Email Address: diana@medvinresearch.com
Upland
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-301) and (HZNP-DAZ-303)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Eric Lee, MD
Inland Rheumatology Clinical Trials Incorporated
1238 East Arrow Highway, Upland,
California 91786
Contact: Carlos Alvarez
Phone: (909) 296-8700
Email Address: calvarez@irclinicaltrials.com
Denver
Deucravacitinib (IM011-1069) Phase 3
Deucravacitinib (IM011-1069)
Bristol Myers Squibb
Sjögren’s Clinical Trial (Systemic)
Christopher Antolini, MD
Denver Arthritis Clinic
200 Spruce Street Suite 100, Denver,
Colorado 80230
Contact: Theresa Hernandez
Phone: (303) 394-2828
Email Address: thernandez@dacdenver.com
Fort Collins
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-301) and (HZNP-DAZ-303)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Michael Thakor, MD
Tekton Research, LLC - Fort Collins - PPDS
2121 E Harmony Rd Unit 360, Fort Collins,
Colorado 80528-3404
Contact: Tamra Meurer
Phone: (970) 267-9799
Email Address: tamra.meurer@tektonresearch.com
Bradenton
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-301) and (HZNP-DAZ-303)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Eric Folkens, MD
Bradenton Research Center Inc
3924 9th Ave W, Bradenton,
Florida 34205-1704
Contact: Gloria Carlbert
Phone: (941) 708-0005
Email Address: gloriacarlbert@bradentonresearch.com
Bradenton
Otsuka Phase 2 Study
Sibeprenlimab
Otsuka Pharmaceutical
Eric Folkens
Bradenton Research Center Inc
3924 9th Ave W, Bradenton,
Florida 34205-1704
Contact: Gloria Carlbert
Phone: +1 941-708-0005
Email Address: gloriacarlbert@bradentonresearch.com
Brandon
Otsuka Phase 2 Study
Sibeprenlimab
Otsuka Pharmaceutical
Vipul Joshi
Bay Area Arthritis and Osteoporosis
1355 Providence Rd, Brandon,
Florida 33511-4885
Contact: Esperanza Snelling
Phone: +1 813-651-4441
Email Address: esperanzas@baao.org
Clearwater
Deucravacitinib (IM011-1069) Phase 3
Deucravacitinib (IM011-1069)
Bristol Myers Squibb
Sjögren’s Clinical Trial (Systemic)
Robert Levin, MD
Clinical Research of West Florida
2147 NE Coachman Road, Clearwater,
Florida 33765
Contact: Maartje Brucculeri
Phone: (727) 466-0078
Email Address: mbrucculeri@crwf.com
Clearwater
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-301) and (HZNP-DAZ-303)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Robert Levin, MD
Clinical Research of West Florida - Clearwater
2147 NE Coachman Road, Clearwater,
Florida 33765-2616
Contact: Jessica Mayfield
Phone: (727) 466-0078
Email Address: jmayfield@crwf.com
Hollywood
Otsuka Phase 2 Study
Sibeprenlimab
Otsuka Pharmaceutical
Mark Jaffe
GNP Research – Florida
9900 Stirling Rd, Hollywood,
Florida 33024-8065
Contact: Veronica Rincon
Phone: +1 561-447-0614
Email Address: rinconv@brcrglobal.com
Miami
Phase 2 Study
HZN-1116 (HZNP-HZN-1116-201)
Horizon Therapeutics, now part of Amgen
Sjögren’s Disease (moderate to severe symptomatic and/or systemic disease) Clinical Trial
Damian Casadesus, MD, PhD
Life Arc Research
860 NW 42nd Ave Suite 302, Miami,
Florida 33126
Contact: Deybis Padron
Phone: (305) 874-7401
Email Address: dpadron@lifearcresearch.health
Miami
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-301)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Eric Greidinger, MD
University of Miami- Leonard M. Miller School of Medicine
1120 NW 14th St., Miami,
Florida 33136
Contact: Michael Mijares
Phone: (305) 243-6405
Email Address: mmijares74@med.miami.edu
New Port Richey
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-301)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Cathy Barnes, MD
Suncoast Clinical Research
5604 Gulf Dr, New Port Richey,
Florida 34652-4020
Contact: Shonte Jones, LPN
Phone: (727) 789-2784 x23
Email Address: sjones@suncoastclinicalresearch.com
Ormond Beach
Phase 2 Study
HZN-1116 (HZNP-HZN-1116-201)
Horizon Therapeutics, now part of Amgen
Sjögren’s Disease (moderate to severe symptomatic and/or systemic disease) Clinical Trial
Michael Kohen, MD
Millennium Research
1545 Hand Ave Ste B2, Ormond Beach,
Florida 32174-1140
Contact: Anastasiia Simpson-Adamova
Phone: (386) 672-1985
Email Address: anamillenium1@gmail.com
Plantation
Phase 2 Study
HZN-1116 (HZNP-HZN-1116-201)
Horizon Therapeutics, now part of Amgen
Sjögren’s Disease (moderate to severe symptomatic and/or systemic disease) Clinical Trial
Guillermo Valenzuela, MD
IRIS Research and Development LLC
140 SW 84th Ave Ste B, Plantation,
Florida 33324-2736
Contact: Jhon Galindo
Phone: (954) 476-2338 x109
Email Address: jgalindo@irisrheumatology.com
Sarasota
Deucravacitinib (IM011-1069) Phase 3
Deucravacitinib (IM011-1069)
Bristol Myers Squibb
Sjögren’s Clinical Trial (Systemic)
Jaishree Manohar
Sarasota Arthritis Center
1945 Versailles St Suite 101, Sarasota,
Florida 34239
Contact: Katie Decker
Phone: (941)365-0770
Email Address: katie@arthritiscenters.net
St. Petersburg
Otsuka Phase 2 Study
Sibeprenlimab
Otsuka Pharmaceutical
Robert Levin
Clinical Research of West Florida Inc – Clearwater
4751 66th St. N., St. Petersburg,
Florida 33709
Contact: Carrie Rycort
Phone: +1 727-347-8839
Email Address: crycort@accelclinical.com
Tamarac
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-301)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Kevin Stone, MD
West Broward Rheumatology Associates, Inc.
7431 N University Drive, Tamarac,
Florida 33321
Contact: Rochelle Durfy
Phone: (954) 545-8400
Email Address: durfywbra@gmail.com
Tamarac
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-303)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Kevin Stone, MD
West Broward Rheumatology Associates, Inc.
7431 N University Drive Ste 300, Tamarac,
Florida 33321-2956
Contact: Jennifer Perez
Phone: (954) 545-8400
Email Address: jperezwbra@gmail.com
Tampa
Otsuka Phase 2 Study
Sibeprenlimab
Otsuka Pharmaceutical
Edgard Janer
Vantage Clinical Trials
4730 N Habana Ave, Tampa,
Florida 33614
Contact: Joanna Vega
Phone: +1 813-773-5867
Email Address: jvega@vantagetrials.com
Tampa
Phase 2 Study
HZN-1116 (HZNP-HZN-1116-201)
Horizon Therapeutics, now part of Amgen
Sjögren’s Disease (moderate to severe symptomatic and/or systemic disease) Clinical Trial
Shanmugapriya Reddy, MD
Clinical Research of West Florida Inc - Tampa
605 N Howard Ave, Tampa,
Florida 33606-1246
Contact: Abby Carlson
Phone: (813) 870-1292
Email Address: acarlson@crwf.com
Tampa
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-301) and (HZNP-DAZ-303)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Michael Burnette, MD
BayCare Medical Group Primary Care and Rheumatology - Tampa
4612 N Habana Ave, Tampa,
Florida 33614-7101
Contact: Tori Norris
Phone: (813) 840-3600
Email Address: tori.edwards@baycare.com
Augusta
Deucravacitinib (IM011-1069) Phase 3
Deucravacitinib (IM011-1069)
Bristol Myers Squibb
Sjögren’s Clinical Trial (Systemic)
Elena Schiopu, MD
Augusta University
1120 15th St, Augusta,
Georgia 30912
Contact: Michelle Collins
Phone: (706) 721-1075
Email Address: mcollins2@augusta.edu
Rockford
Otsuka Phase 2 Study
Sibeprenlimab
Otsuka Pharmaceutical
Saad Tariq
OrthoIllinois, LTD
5875 E Riverside Blvd, Rockford,
Illinois 61114-4937
Contact: Heather Hackman
Phone: +1 815-381-7468
Email Address: heather.hackman@orthoillinois.com
Rockford
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-301)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Saad Tariq, MD
OrthoIllinois, LTD
5875 E Riverside Blvd, Rockford,
Illinois 61114-4937
Contact: Heather Hackman
Phone: (815) 381-7468
Email Address: heather.hackman@orthoillinois.com
Skokie
Otsuka Phase 2 Study
Sibeprenlimab
Otsuka Pharmaceutical
John Berry
Arnold Arthritis and Rheumatology
4709 Golf Road, Skokie,
Illinois 60076-1231
Contact: Hena Kauser
Phone: +1 847-869-7233
Email Address: hkauser@arnoldarthritis.com
Skokie
Deucravacitinib (IM011-1069) Phase 3
Deucravacitinib (IM011-1069)
Bristol Myers Squibb
Sjögren’s Clinical Trial (Systemic)
Robert Hozman, MD
Clinic of Robert Hozman/Clinical Investigation Specialists Inc.
4709 Golf Road, Skokie,
Illinois 60076
Contact: Megi Stafa
Phone: (847) 599-2492
Email Address: mstafa@cisresearch.com
Kansas City
Deucravacitinib (IM011-1069) Phase 3
Deucravacitinib (IM011-1069)
Bristol Myers Squibb
Sjögren’s Clinical Trial (Systemic)
Ghaith Noaiseh, MD
University of Kansas Medical Center
3901 Rainbow Blvd., Kansas City,
Kansas 60160
Contact: Vanessa Verschelden
Phone: (913) 588-0653
Email Address: vbarrientos@kumc.edu
Baton Rouge
Otsuka Phase 2 Study
Sibeprenlimab
Otsuka Pharmaceutical
Saravanan Thiagarajan
Ochsner Clinic Foundation – Baton Rouge
10310 The Grove Blvd, Baton Rouge,
Louisiana 70836
Contact: Kevin Lindsey
Phone: +1 225-761-5375
Email Address: kevin.lindsey@ochner.org
Baton Rouge
Deucravacitinib (IM011-1069) Phase 3
Deucravacitinib (IM011-1069)
Bristol Myers Squibb
Sjögren’s Clinical Trial (Systemic)
Saravanan Thiagarajan, MD
Ochsner Health Center - Baton Rouge
10310 The Grove Blvd., Baton Rouge,
Louisiana 70836
Contact: Ashunti Pearson
Phone: (225) 761-5278
Email Address: aspearson@ochsner.org
Lake Charles
Phase 2 Study
HZN-1116 (HZNP-HZN-1116-201)
Horizon Therapeutics, now part of Amgen
Sjögren’s Disease (moderate to severe symptomatic and/or systemic disease) Clinical Trial
Enrique Mendez, MD
Accurate Clinical Research - Lake Charles
1727 Imperial Blvd Bldg 1 # STE B, Lake Charles,
Louisiana 70605-5393
Contact: Jacob Seep
Phone: (337) 312-8617
Email Address: jseep@accurateclinicalresearch.com
Boston
Study #00002230
Dr. Addy Alt-Holland and Dr. Mabi Singh
Tufts University School of Dental Medicine
1 Kneeland Street, Boston,
Massachusetts 02111
Contact: Tiffany Bairos, Lead Coordinator
Phone: (617) 636-2408
Boston
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-301)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Athena Papas, MD
Tufts Medical Center - Rheumatology Research Office
1 Kneeland Street, Boston,
Massachusetts 02111
Contact: Joseph Cimmino
Phone: (617) 636-6515
Email Address: joseph.cimmino@tufts.edu
Boston
Otsuka Phase 2 Study
Sibeprenlimab
Otsuka Pharmaceutical
Athena Papas
Tufts University School of Dental Medicine
1 Kneeland St, Boston,
Massachusetts 02111-1527
Contact: Elizabeth Tzavaras
Phone: +1 617-636-3931
Email Address: elizabeth.tzavaras@tufts.edu
Boston
Phase 2 Study
HZN-1116 (HZNP-HZN-1116-201)
Horizon Therapeutics, now part of Amgen
Sjögren’s Disease (moderate to severe symptomatic and/or systemic disease) Clinical Trial
Athena Papas, DDS, DMD, MD, PhD
Tufts Medical Center - PPDS
1 Kneeland St, Boston,
Massachusetts 02111-1527
Contact: Joseph Cimmino
Phone: (617) 636-3931
Email Address: joseph.cimmino@tufts.edu
Baltimore
Deucravacitinib (IM011-1069) Phase 3
Deucravacitinib (IM011-1069)
Bristol Myers Squibb
Sjögren’s Clinical Trial (Systemic)
Thomas Grader-Beck, MD, PhD
Johns Hopkins Medicine - Jerome L. Greene Sjögren's Center
5200 Eastern Ave Ste 4100 Rm 413, Baltimore,
Maryland 21224-2746
Contact: Jennifer Reed
Phone: (410) 550-6492
Email Address: jreed52@jhu.edu
Bethesda
STUDY # 20-D-0131
National Institute of Dental and Craniofacial Research
Blake M Warner, D.D.S
National Institute of Dental and Craniofacial Research
NIH Clinical Center, Bethesda,
Maryland
Contact: Sasha Clary
Phone: (301) 529 -7924
Email Address: sasha.clary@nih.gov
Columbia
Phase 2 Study
HZN-1116 (HZNP-HZN-1116-201)
Horizon Therapeutics, now part of Amgen
Sjögren’s Disease (moderate to severe symptomatic and/or systemic disease) Clinical Trial
James Bellor Jr., MD
Kur Research at Columbia Medical
5450 Knoll North Dr Ste 270, Columbia,
Maryland 21045-2394
Contact: Brittney Lewis-Weekes
Phone: (410) 964-6115
Email Address: blewis-weekes@kurr.com
St. Clair Shores
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-301) and (HZNP-DAZ-303)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Amar Majjhoo, MD
Shores Rheumatology
29200 Harper Ave, St. Clair Shores,
Michigan 48081
Contact: Danielle Dickey
Phone: (586) 777-6841
Email Address: ddickey@researchmi.com
Eagan
Deucravacitinib (IM011-1069) Phase 3
Deucravacitinib (IM011-1069)
Bristol Myers Squibb
Sjögren’s Clinical Trial (Systemic)
David Ridley, MD
St. Paul Rheumatology
2854 Hwy. 55, Ste. 190, Eagan,
Minnesota 55121
Contact: Zsofia Czegledi
Phone: (651) 361-8659
Email Address: zsofia@sprdrem.com
Kansas City
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-301) and (HZNP-DAZ-303)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Tina Shah, MD
Kansas City Physician Partners- 8350 N Saint Clair Ave
8350 N Saint Clair Ave Ste 100, Kansas City,
Missouri 64151-5102
Contact: Micah Judd
Phone: (816) 268-7512
Email Address: micah.judd@azathritis.com
Charlotte
Otsuka Phase 2 Study
Sibeprenlimab
Otsuka Pharmaceutical
Emily Box
DJL Clinical Research PLLC
431 N Wendover Rd, Charlotte,
North Carolina 28211-1064
Contact: Ayushi Patel
Phone: +1 704-247-9179
Email Address: ayushi.patel@djlresearch.com
Charlotte
Phase 2 Study
HZN-1116 (HZNP-HZN-1116-201)
Horizon Therapeutics, now part of Amgen
Sjögren’s Disease (moderate to severe symptomatic and/or systemic disease) Clinical Trial
Emily Box, MD
DJL Clinical Research PLLC
431 N Wendover Rd, Charlotte,
North Carolina 28211-1064
Contact: Jennifer Bryson
Phone: (704) 247-9179
Email Address: jennifer.bryson@djlresearch.com
Durham
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-301)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Teresa Tarrant, MD
Duke Early Phase Clinical Research Unit
200 Trent Drive, Durham,
North Carolina 27710
Contact: Julianna Ethridge
Phone: (919) 681-5871
Email Address: julianna.ethridge@duke.edu
Salisbury
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-301) and (HZNP-DAZ-303)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Nilesh Patel, MD
Onsite Clinical Solutions, LLC Salisbury
611 Mocksville Ave., Salisbury,
North Carolina 28144-2705
Contact: Pratiksha Singh
Phone: (800) 785-3150
Email Address: psingh@onsiteclinical.com
Summit
Deucravacitinib (IM011-1069) Phase 3
Deucravacitinib (IM011-1069)
Bristol Myers Squibb
Sjögren’s Clinical Trial (Systemic)
Elliot Rosenstein, MD
Institute for Rheumatic & Autoimmune Diseases, Overlook Medical Center
33 Upper Overlook Rd # 211, Summit,
New Jersey 07901
Contact: Cynthia Ramdass
Phone: (908) 598-7940
Email Address: cynthia.ramdass@atlantichealth.org
Voorhees
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-301) and (HZNP-DAZ-303)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Ruchika Patel, MD
Arthritis, Rheumatic & Bone Disease Associates
2301 Evesham Road, Voorhees,
New Jersey 08043
Contact: Jessica Reibel
Phone: (856) 424-5005
Email Address: jreibel@arbda.com
Albuquerque
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-303)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Leroy Pacheco, MD
Albuquerque Center for Rheumatology
711 Encino Place NE, Albuquerque,
New Mexico 87102
Contact: Tianna Dunlap
Phone: (505) 224-2710
Email Address: tdunlap@abqrheum.net
Albuquerque
Otsuka Phase 2 Study
Sibeprenlimab
Otsuka Pharmaceutical
Leroy Pacheco
Albuquerque Center for Rheumatology
1617 University Blvd NE, Albuquerque,
New Mexico 87102
Contact: Tianna Dunlap
Phone: +1 505-341-4148 ext. 228
Email Address: vjackson@abqrheum.net
Las Vegas
Otsuka Phase 2 Study
Sibeprenlimab
Otsuka Pharmaceutical
Walter Chatham
Kirk Kerkorian School of Medicine UNLV
1707 W. Charleston Blvd, Las Vegas,
Nevada 89102
Contact: Priscilla Herrera
Phone: +1 702-671-5093
Email Address: priscilla.herrera@unlv.edu
Brooklyn
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-301)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
David Goddard, MD
NYU Langone Health- Joseph S. and Diane H. Steinberg Ambulatory Care Center
186 Joralemon Street, 8th floor, Brooklyn,
New York 11201
Contact: Debra London
Phone: (929) 455-2585
Email Address: studycoordinatorgoddard@gmail.com
Mineola
Deucravacitinib (IM011-1069) Phase 3
Deucravacitinib (IM011-1069)
Bristol Myers Squibb
Sjögren’s Clinical Trial (Systemic)
Steve Carsons, MD
NYU Langone Hospital - Long Island
101 Mineola Blvd, Mineola,
New York 11501
Contact: Melissa Allman
Phone: (516) 663-9582
Email Address: melissa.allman@nyulangone.org
New York
Phase 2 Study
HZN-1116 (HZNP-HZN-1116-201)
Horizon Therapeutics, now part of Amgen
Sjögren’s Disease (moderate to severe symptomatic and/or systemic disease) Clinical Trial
Frederick Ast, MD
Pioneer Clinical Research NY
37 E 30th St Ste 1A, New York,
New York 10016-7313
Contact: Nilay Mehta
Phone: (321) 578-1144
Email Address: nmehta@pioneerclinicalny.com
Miamisburg
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-301) and (HZNP-DAZ-303)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Chacko Alappatt, MD
Arthritis & Osteoporosis Center of Southwest Ohio - Miamisburg
2960 Ferndown Dr, Miamisburg,
Ohio 45342-3585
Contact: Megan Heffner
Phone: (513) 420-8195
Email Address: megan.heffner@statresearch.com
Toledo
Otsuka Phase 2 Study
Sibeprenlimab
Otsuka Pharmaceutical
Aya Abugharbyeh
Ruppert Health Center
3000 Arlington Avenue, Toledo,
Ohio 43614
Contact: Jennifer Gilmore
Phone: +1 419-383-6761
Email Address: jennifer.gilmore@utoledo.edu
Toledo
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-301)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Bashar Kahaleh, MD
University of Toledo Medical Center
3000 Arlington Avenue, Toledo,
Ohio 43614
Contact: Jennifer Gilmore
Phone: (419) 383-6761
Email Address: jennifer.gilmore@utoledo.edu
Vandalia
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-301) and (HZNP-DAZ-303)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Sanford Wolfe, DO
STAT Research
600 Aviator Ct Ste 100B, Vandalia,
Ohio 45377-9474
Contact: Laura Earle
Phone: (856) 424-5005
Email Address: laura.earle@statresearch.com
Vandalia
Otsuka Phase 2 Study
Sibeprenlimab
Otsuka Pharmaceutical
Sanford Wolfe
STAT Research
600 Aviator Ct, Vandalia,
Ohio 45377-9474
Contact: Laura Earle
Phone: +1 937-223-4229
Email Address: laura.earle@statresearch.com
Duncansville
Deucravacitinib (IM011-1069) Phase 3
Deucravacitinib (IM011-1069)
Bristol Myers Squibb
Sjögren’s Clinical Trial (Systemic)
Alan Kivitz, MD
Altoona Center for Clinical Research
175 Meadowbrook Ln, Duncansville,
Pennsylvania 16635
Contact: Heather Breon
Phone: (814) 693-0300
Email Address: heatherbreon@altoonaresearch.com
Duncansville
Phase 2 Study
HZN-1116 (HZNP-HZN-1116-201)
Horizon Therapeutics, now part of Amgen
Sjögren’s Disease (moderate to severe symptomatic and/or systemic disease) Clinical Trial
Alan Kivitz, MD
Altoona Center for Clinical Research
175 Meadowbrook Ln, Duncansville,
Pennsylvania 16635-8445
Contact: Lisa Claycomb
Phone: (814) 693-0300
Email Address: altoonaresearch@gmail.com
San Juan
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-301) and (HZNP-DAZ-303)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Gregorio Cortes-Maisonet, MD
GCM Medical Group
Urb. Floral Park #62 Calle Jose Marti, San Juan,
Puerto Rico 00917
Contact: Bryan Rivera Otero
Phone: (787) 936-2100 EXT 10
Email Address: brivera@gcmmedical.com
San Juan
Deucravacitinib (IM011-1069) Phase 3
Deucravacitinib (IM011-1069)
Bristol Myers Squibb
Sjögren’s Clinical Trial (Systemic)
Oscar Soto-Raices, MD
Mindful Medical Research
576 Cesar Gonzalez Ave, San Juan,
Puerto Rico 00918
Contact: Franco Alonso
Phone: (787) 765-9034
Email Address: falonso@mmr-pr.com
San Juan
Deucravacitinib (IM011-1069) Phase 3
Deucravacitinib (IM011-1069)
Bristol Myers Squibb
Sjögren’s Clinical Trial (Systemic)
Gregorio Cortes-Maisonet, MD
GCM Medical Group
62 Calle Jose Marti, San Juan,
Puerto Rico 00917
Contact: Luis Martinez Miranda
Phone: (787) 598-5853
Email Address: lmiranda@gcmmedical.com
Jackson
Phase 2 Study
HZN-1116 (HZNP-HZN-1116-201)
Horizon Therapeutics, now part of Amgen
Sjögren’s Disease (moderate to severe symptomatic and/or systemic disease) Clinical Trial
Jacob Aelion, MD
West Tennessee Research Institute
369 N Parkway Ste 400, Jackson,
Tennessee 38305-2883
Contact: Sherry Wiggins
Phone: (731) 633-0045
Email Address: swiggins@arthritisclinic.org
Murfreesboro
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-301)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Marcus Owen, MD
Murfreesboro Medical Clinic- Westlawn
3325 Shores Road, Murfreesboro,
Tennessee 37128
Contact: Jennifer Neal
Phone: (212) 427-6656 EXT 627
Email Address: jennifer.neal@azarthritis.com
Allen
Deucravacitinib (IM011-1069) Phase 3
Deucravacitinib (IM011-1069)
Bristol Myers Squibb
Sjögren’s Clinical Trial (Systemic)
Megha Patel-Banker, MD
Arthritis & Rheumatology Research Institute, PLLC
981 TX-121 Suite #3150, Allen,
Texas 75013
Contact: Guadalupe Cindo
Phone: (972) 798-8553
Email Address: l.cindo@dfwarthritis.com
Allen
Otsuka Phase 2 Study
Sibeprenlimab
Otsuka Pharmaceutical
John Lavery
Allen Arthritis
997 Raintree Cir, Allen,
Texas 75013-4949
Contact: Aarsheya Amin
Phone: +1 214-407-8640
Email Address: aamin@stryderesearch.com
Amarillo
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-301) and (HZNP-DAZ-303)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Constantine Saadeh, MD
Amarillo Center For Clinical Research - ClinEdge
6842 Plum Creek Dr, Amarillo,
Texas 79124-1601
Contact: Alina Noynouanpheng
Phone: (806) 352-2453
Email Address: anoynouanpheng@allergyarts.com
Austin
Phase 2 Study
HZN-1116 (HZNP-HZN-1116-201)
Horizon Therapeutics, now part of Amgen
Sjögren’s Disease (moderate to severe symptomatic and/or systemic disease) Clinical Trial
Paul Pickrell, MD
Tekton Research, LLC - Austin - PPDS
4534 Westgate Boulevard, Suite 110, Austin,
Texas 78745
Contact: John Luna
Phone: (512) 388-5717
Email Address: jluna@tektonresearch.com
Austin
Otsuka Phase 2 Study
Sibeprenlimab
Otsuka Pharmaceutical
Paul Pickrell
Tekton Research, LLC – West Gate Blvd – Austin – PPDS
4534 West Gate Blvd, Austin,
Texas 78745-1485
Contact: Stephanie Garcia
Phone: +1 512-388-5717
Email Address: sgarcia@tektonresearch.com
Baytown
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-301) and (HZNP-DAZ-303)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Sabeen Najam, MD
Accurate Clinical Management- Baytown
1610 W Baker Road, Suite C, Baytown,
Texas 77521
Contact: Mariela Martinez
Phone: (281) 851-7088
Email Address: mmartinez@accurateclinicalresearch.com
Grapevine
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-301)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Uzma Syeda, MD
Precision Comprehensive Clinical Research Solutions
1501 W Northwest Hwy, Grapevine,
Texas 76051-3143
Contact: Akhil Gangasani
Phone: (972) 299-8399
Email Address: akhilgangasani@pccrsolutions.com
Houston
Phase 2 Study
HZN-1116 (HZNP-HZN-1116-201)
Horizon Therapeutics, now part of Amgen
Sjögren’s Disease (moderate to severe symptomatic and/or systemic disease) Clinical Trial
Michelle Eisenberg, DO
Prolato Clinical Research Center
11920 Astoria Blvd Ste 200, Houston,
Texas 77089-6155
Contact: Romeo Parada
Phone: (832) 338-9118
Email Address: rparada@prolato.org
Houston
Phase 2 Study
HZN-1116 (HZNP-HZN-1116-201)
Horizon Therapeutics, now part of Amgen
Sjögren’s Disease (moderate to severe symptomatic and/or systemic disease) Clinical Trial
Nada Mustafa, MD
Trio Clinical Trials
1235 North Loop W Ste 220, Houston,
Texas 77008-1772
Contact: Zitiali Alanis
Phone: (713) 869-1825
Email Address: zalanis@trioclinical.com
Houston
Otsuka Phase 2 Study
Sibeprenlimab
Otsuka Pharmaceutical
Philip Waller
Accurate Clinical Research
11003 Resource Parkway, Houston,
Texas 77089
Contact: Eli Torok
Phone: +1 281-481-8557
Email Address: etorok@accurateclinicalresearch.com
Katy
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-301) and (HZNP-DAZ-303)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Maryam Khawari, MD
R & H Clinical Research-777 S Fry Rd
777 S Fry Road Ste 102, Katy,
Texas 77450
Contact: Denise Rodriguez
Phone: (713) 367-2791
Email Address: denise@rhclinicalresearch.com
Katy
Otsuka Phase 2 Study
Sibeprenlimab
Otsuka Pharmaceutica
Maryam Khawari
R & H Clinical Research
777 S Fry Road, Katy,
Texas 77450
Contact: Denise Rodriguez
Phone: +1 713-367-2791
Email Address: denise@rhclinicalresearch.com
Katy
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-303)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Tara Rizvi, MD
Houston Rheumatology and Arthritis Specialists, PLLC
23920 Katy Fwy Ste 440, Katy,
Texas 77494-1341
Contact: Ana Gutierrez
Phone: (281) 944-3610
Email Address: ana@biopharmainfo.net
Katy
Otsuka Phase 2 Study
Sibeprenlimab
Otsuka Pharmaceutical
Aman Kugasia
Accurate Clinical Management, LLC
2630 N Mason Rd, Katy,
Texas 77449
Contact: Karla Bonilla
Phone: +1 281-240-1045
Email Address: kbonilla@accurateclinicalresearch.com
Katy
Phase 2 Study
HZN-1116 (HZNP-HZN-1116-201)
Horizon Therapeutics, now part of Amgen
Sjögren’s Disease (moderate to severe symptomatic and/or systemic disease) Clinical Trial
Maryam Khawari, MD
R & H Clinical Research-Katy
777 S Fry Rd Ste 102, Katy,
Texas 77450-2297
Contact: Imran Chunawala
Phone: (713) 367-2791
Email Address: imran@rhclinicalresearch.com
McAllen
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-301) and (HZNP-DAZ-303)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Elvin Garcia, MD
Valley Arthritis Center
811 E Fern Ave, McAllen,
Texas 78501
Contact: Clarisa Garza
Phone: (281) 944-3610
Email Address: cgarza@biopharmainfo.net
San Antonio
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-301)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Augustin Escalante, MD
University of Texas - San Antonio - Health Science Center
7703 Floyd Curl Drive, San Antonio,
Texas 78229
Contact: Jose Restrepo
Phone: (210) 567-4656
Email Address: restreposuar@uthscsa.edu
The Woodlands
Otsuka Phase 2 Study
Sibeprenlimab
Otsuka Pharmaceutical
Tamar Brionez
Advanced Rheumatology of Houston
10857 Kuykendahl Road, The Woodlands,
Texas 77382
Contact: Elizabeth Soriano
Phone: +1 936-681-4882
Email Address: elizabeth@advancedrheum.com
The Woodlands
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-303)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Tamar Brionez, MD
Advanced Rheumatology of Houston
10857 Kuykendahl Road Ste 160, The Woodlands,
Texas 77382
Contact: Elizabeth Soriano
Phone: (936) 681-4882
Email Address: elizabeth@advancedrheum.com
Tomball
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-301)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Shaikh Ali, MD
DM Clinical Research - Tomball - PPDS
13414 Medical Complex Dr Ste 2, Tomball,
Texas 77375-3333
Contact: Bylinda Vo-Le
Phone: (281) 517-0550
Email Address: bylinda.vo-le@dmclinical.com
Tomball
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-303)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Shaikh Ali, MD
DM Clinical Research - Migraine and COPD - PPDS
13414 Medical Complex Dr Ste 10, Tomball,
Texas 77375-3333
Contact: Sahithi Bethelli
Phone: (281) 517-0550
Email Address: sahithi.bethelli@dmclinical.com
Bothell
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-301)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Jeff Peterson, MD
Western Washington Medical Group
1909 214th St SE Ste 211, Bothell,
Washington 98021-4418
Contact: Aubrey Hubble
Phone: (425) 248-2635
Email Address: ahubble@wwmedgroup.com
Bothell
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-303)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Jeff Peterson, MD
Western Washington Medical Group
1909 214th St SE Ste 211, Bothell,
Washington 98021-4418
Contact: Kavya Rudra
Phone: (425) 248-2635
Email Address: krudra@wwmedgroup.com
Seattle
Deucravacitinib (IM011-1069) Phase 3
Deucravacitinib (IM011-1069)
Bristol Myers Squibb
Sjögren’s Clinical Trial (Systemic)
Kwanghoon Bobby Han, MD
University of Washington Medical Center
1959 NE Pacific Street, Seattle,
Washington 98195
Contact: Megan Tran
Phone: (206) 616-5330
Email Address: megant99@medicine.washington.edu
Spokane
Deucravacitinib (IM011-1069) Phase 3
Deucravacitinib (IM011-1069)
Bristol Myers Squibb
Sjögren’s Clinical Trial (Systemic)
Michael Coan, DO
Arthritis Northwest
105 W 8th Ave Ste 6080, Spokane,
Washington 99204
Contact: Jace Cullley
Phone: (509) 838-6500 EXT 119
Email Address: jculley@arthritisnw.com
Madison
Phase 2 Study
HZN-1116 (HZNP-HZN-1116-201)
Horizon Therapeutics, now part of Amgen
Sjögren’s Disease (moderate to severe symptomatic and/or systemic disease) Clinical Trial
Sara McCoy, MD
University Of Wisconsin - Madison
600 Highland Avenue, Madison,
Wisconsin 53792
Contact: Matt Gilles
Phone: (608) 263-4505
Email Address: mpgilles@clinicaltrials.wisc.edu
Beckley
Oasiz Phase 3 Study
Dazodalibep (HZNP-DAZ-301) and (HZNP-DAZ-303)
Horizon Therapeutics, now part of Amgen
Sjögren’s Clinical Trial (Systemic)
Wassim Saikali, MD
Rheumatology and Pulmonary Clinic
421 Carriage Dr, Beckley,
West Virginia 25801-2805
Contact: Catie Webb
Phone: (304) 256-0245
Email Address: webb.catie421@gmail.com